Adjunct to diet in treatment of elevated total cholesterol, serum triglycerides, and LDL cholesterol and to increase HDL-C in patients with primary hypercholesterolemia (types IIa and IIb) and mixed dyslipidemia and primary dysbetalipoproteinemia, whose response to dietary restriction of saturated fat and cholesterol and other nonpharmacologic measures has not been adequate

To reduce total cholesterol and LDL-C in patients with homozygous familial hypercholesterolemia as adjunct to lipid-lowering treatments

Reduction of risk of MI and stroke in patients with type 2 diabetes and in those with multiple risk factors for CAD (such as age 55 or older, smoking, hypertension, low HDL-C, family history of early CAD) but no clinical evidence of CAD

Adjunct to diet to treat elevated serum triglyceride levels (Fredrickson Type IV)

Adjunct to diet in treatment of boys and postmenarchal girls ages 10–17 with
heterozygous familial cholesterolemia if diet alone is not adequate to control lipid levels and LDL-C levels are 190 mg/dL or greater or if LDL-C level is 160 mg/dL or greater and there is a family history of premature CV disease or the child has two or more risk factors for the development of coronary disease

Reduction of risk of MI, fatal and nonfatal stroke, revascularization procedures, heart failure, hospitalization, and angina in patients with clinically evident CAD

Prevention of CV disease in adults without clinically evident coronary disease but with multiple risk factors for CAD; to reduce the risk of MI and risk for revascularization procedures and angina